Impact of anxiety and depression on respiratory symptoms  by Leander, Mai et al.
Respiratory Medicine (2014) 108, 1594e1600Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate /rmedImpact of anxiety and depression on
respiratory symptoms
Mai Leander a,h,*, Erik Lampa a, Anna Rask-Andersen a,
Karl Franklin b, Thorarinn Gislason c,d, Anna Oudin e,
Cecilie Svanes f, Kjell Tore´n g, Christer Janson ha Department of Medical Sciences, Occupational and Environmental Medicine, Uppsala University,
Uppsala, Sweden
b Surgical and Perioperative Sciences, Department of Surgery, Umea˚ University,Umea˚ Sweden
c Department of Respiratory Medicine and Sleep, Landspitali e The National University Hospital of
Iceland, Reykjavik, Iceland
d Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
e Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, Umea˚
University, Sweden
f Bergen Respiratory Research Group, Institute of Medicine, University of Bergen and Department of
Occupational Medicine, Haukeland University Hospital Bergen, Bergen, Norway
g Section of Occupational and Environmental Medicine University of Gothenburg, Box 414, 405 30
Gothenburg, Sweden
h Department of Medical Sciences, Respiratory Medicine and Allergology, Uppsala University, Uppsala,
SwedenReceived 25 April 2014; accepted 5 September 2014
Available online 16 September 2014KEYWORDS
Asthma;
Anxiety;
Depression* Corresponding author. Department
Sweden. Tel.: þ46 8 587 516 64.
E-mail address: mai.leander@rkh.s
http://dx.doi.org/10.1016/j.rmed.20
0954-6111/ª 2014 Elsevier Ltd. All rigSummary
Psychological factors such as anxiety and depression are prevalent in patients with asthma.
The purpose of this study was to investigate the relationship between respiratory symptoms
and psychological status and to estimate the importance of psychological status in comparison
with other factors that are known to be associated with respiratory symptoms.
This study included 2270 subjects aged 20e44 (52% female) from Sweden, Iceland, and Nor-
way. Each participant underwent a clinical interview including questions on respiratory symp-
toms. Spirometry and methacholine challenge were performed. Symptoms of depression and
anxiety were measured using the Hospital Anxiety and Depression Scale (HADS).
Eighty-two percent of the subjects reported no anxiety or depression whatsoever, 11% re-
ported anxiety, 2.5% depression and 4% reported both anxiety and depression. All respiratory
symptoms, such as wheezing, breathlessness and nightly symptoms, were more common, at aof Medical Sciences, Respiratory Medicine and Allergology, Uppsala University, SE-751 85 Uppsala,
e (M. Leander).
14.09.007
hts reserved.
Impact of anxiety and depression 1595statistically significant level, in participants who had depression and anxiety, even after ad-
justing for confounders (ORs 1.33e1.94). The HADS score was the most important determinant
for nightly symptoms and attacks of breathlessness when at rest whereas bronchial responsive-
ness was the most important determinant for wheezing, and breathlessness when wheezing.
The probability of respiratory symptoms related to HADS score increased with increasing HADS
score for all respiratory symptoms.
In conclusion, there is a strong association between respiratory symptoms and psychological
status. There is therefore a need for interventional studies designed to improve depression and
anxiety in patients with respiratory symptoms.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Respiratory symptoms are common. For instance the median
prevalence of having had wheezing in the last 12 months was
over 20% in a large international study of 20e44 year old
adults [1]. Respiratory symptoms are often a manifestation
of respiratory diseases such as asthma or Chronic Obstructive
Pulmonary Disease (COPD), but can also exist in patient
without any known respiratory disorder [2].
Respiratory symptoms are associated with bronchial
responsiveness, allergy, obesity and exposures such as
smoking and environmental factors [3]. Less is known about
the association between psychological status and respiratory
symptoms. Asthma has been associated with anxiety and
depression [4]. But in one study having anxiety and depres-
sion was strongly associated with respiratory symptoms but
not with asthma and bronchial responsiveness [5]. The nature
of the relationship between psychological status and respi-
ratory symptoms and the underlying mechanisms are still
unknown [6]. In some studies, psychological symptoms have
been related to a higher risk of developing asthma [7]. Other
studies have indicated that badly controlled asthma and
respiratory symptoms such as breathlessness may lead to
anxiety disorder [8] another study showed there is an asso-
ciation between generalized anxiety disorder and poor
asthma control [9]. Some studies show, however, that respi-
ratory symptoms and psychological symptoms are only loosely
related to each other [10,11]. There are also studies that
indicate that the association between psychological health
and lung function differs between men and women [12].
The purpose of this study was to investigate the rela-
tionship between respiratory symptoms, such as wheezing
and breathlessness, and psychological factors using Hospi-
tal Anxiety Depression Scale (HADS), and also to estimate
the importance of psychological status in comparison with
other well-known factors that are associated with respira-
tory symptoms, such as low lung function, bronchial
responsiveness, smoking, body mass index (BMI) and atopy.Figure 1 Study design.Material and methods
Study design
European Community Respiratory Health Survey (ECRHS) I
and II were designed to determine the prevalence,incidence and risk factors for asthma and allergic disease in
young and middle-aged adults living in Europe and other
parts of the world. ECRHS I [13] was a multicenter study
performed in 48 study centers during 1990e1993. Each
participant was sent a brief questionnaire (Stage 1) and a
random sample of responders was selected to undergo a
more detailed clinical examination (Stage 2). In addition, a
‘symptomatic sample’ reporting symptoms of waking with
shortness of breath, asthma attacks or using asthma
medication in stage 1, was also studied. ECRHS II was a
follow-up study, performed in 29 centers in 14 countries
during 1999e2002, and comprised the participants in the
second stage of ECRHS. The analyses presented here
included 2270 subjects from Sweden, Iceland, and Norway
who participated in ECRHS II (Fig. 1).Measures
Questionnaires
Structured clinical interview. The screening question-
naire and the questionnaire used in the structured inter-
view were based on the International Union against
Tuberculosis and Lung Disease (IUATLD) questionnaire [14].
Each participant underwent a structured clinical interview
including questions on the presence of asthma,
1596 M. Leander et al.respiratory symptoms, and therapy. The full questionnaires
can be found at http://www.ecrhs.org/Quests.htm.
Hospital Anxiety Depression Scale (HADS). Participants in
Sweden, Iceland and Norway were also asked to fill out the
self-reported Hospital Anxiety Depression Scale, HADS
[15e17]. The HADS is a fourteen-item scale that
generates ordinal data. Seven of the items relate to
anxiety and seven relate to depression. Each item is rated
on a 4-point scale: 0, not at all; 1, sometimes; 2, often;
3, all the time; this gives a maximum subscale score of 21
for anxiety and depression, respectively. HADS gives
clinically meaningful results as a psychological screening
tool in clinical group comparisons and correlation studies
with several aspects of disease and quality of life [18].
In the validation of the questionnaire, a score of >7 in
the two subscales has been found to discriminate non cases
from suspected cases [17]. In the present study, we com-
bined the depression and anxiety scale to obtain a com-
bined measure of psychological status [19,20]. HADS has
been validated for Swedish sample [21].
The European Community Respiratory Health Survey II
main questionnaire. Respiratory symptoms were defined
at follow up as answering “yes” to the questions:
 Wheeze
Have you had wheezing or whistling in your chest at any
time in the last 12 months?
 Wheeze and breathlessness
Have you been at all breathless when the wheezing noise
was present?
 Wheeze when not having a cold
Have you had this wheezing or whistling when you did
not have a cold?
 Nocturnal chest tightness
Have you woken up with a feeling of tightness in your
chest at any time in the last 12 months?
 Attack of breathlessness when at rest
Have you had an attack of shortness of breath that came
on during the day when you were at rest at any time in
the last 12 months?
 Attack of breathlessness after activity
Have you had an attack of shortness of breath that came
on following strenuous activity at any time in the last 12
months?
 Nocturnal dyspnea
Have you been woken by an attack of shortness of breath
at any time in the last 12 months?
Asthma
 Doctor’s diagnosed asthma was defined as a positive
answer to both questions: “Have you ever suffered from
asthma?” and “Was this confirmed by a doctor?” [1,22]Smoking history
 Smoking history was investigated by asking subjects
whether they were current smokers, smokers thatquitted smoking between ECRHS I and II, ex-smokers
(stopped smoking before ECRHS I) or never-smokers.Clinical measurements
Spirometry. FEV1 (Forced expiratory volume in 1 s) was
measured using a dry rolling seal Spirometry system (Sensor
medics 2130, Sensor medics, Anaheim, CA, USA) after the
structured interview. Up to five technically acceptable
exhalations were determined. The results were expressed
as percent of predicted using the European Community for
Coal and Steel (ECCS) normal values for spirometry [23]. No
bronchodilator was given before the spirometry.
Bronchial responsiveness. Methacholine challenge was
performed with a Mefar dosimeter (Provocholine, Meth-
apharm, Inc., ON, Canada) after the structured interview.
The participants first inhaled a diluent and doses of meth-
acholine were then inhaled until a 20% fall in postdiluent
FEV1 was observed or the maximum cumulative dose of
2 mg was reached. The degree of bronchial responsiveness
was calculated using a previously described dose slope
where a lower value indicates more responsiveness [24].
Standardization was assured through training seminars
and quality control visits. A more detailed description of
the methods use has been presented previously [25].
Body mass index. Height and weight was measured and
BMI was calculated as weight in kilograms divided by the
square of height in meters.
Atopy. Blood samples were collected for the measure-
ment of serum-specific IgE and total IgE using the
Pharmacia CAP System (Pharmacia Diagnostics, Uppsala,
Sweden) after the interview. Serum samples were stored at
20 C and transferred to a centralized laboratory where
they were tested for specific IgE to house dust mite, grass,
cat and Cladosporium. Atopy was defined as having IgE
(0.35 kU/L) against at least one of the allergens
investigated [26].
Statistical analysis
Associations between different respiratory-related symp-
toms and anxiety/depression were studied using binary
logistic regression. Potential confounding variables were
selected prior to the analyses, based on clinical knowledge
and previous analyses of the ECRHS [3]. First, we fitted a
flexible additive model for each outcome using restricted
cubic splines with four degrees of freedom for the contin-
uous determinants. Knowing that this model might be too
flexible and overfit the data, we decided to either retain
the nonlinear terms or model the determinant linearly,
based on the determinant’s apparent predictive power. A
determinant’s predictive power was defined as the c2-
value obtained from the regression minus the de-
terminant’s degrees of freedom [27]. The rationale behind
this strategy is that it is less damaging to miss-specify the
structure of a determinant whose predictive power is low
than to miss-specify the structure of a powerful
determinant.
Impact of anxiety and depression 1597We then tested three pre-specified interactions: anxi-
ety/depression and sex, anxiety/depression and bronchial
responsiveness, and anxiety/depression and atopy. Inter-
action terms were either retained or removed from the
respective model, based on a global test of no interaction
versus at least one interaction term not equal to zero. We
performed a hierarchical cluster analysis using the fraction
of missing values between any two variables to characterize
the pattern of missing values in the data. Incomplete var-
iables were then imputed under fully conditional specifi-
cation [28]. Computations were done in R with 15
imputations created using the mice package [29].
Only variables with a Spearman correlation > 0.1 with
the variable being imputed were included in the imputation
model for that variable [29].
Ethical approval
Ethical approval was obtained from each center’s regional
research ethical committee. Each participant provided a
written informed consent.
Results
HADS (n Z 2270) was used to divide the study sample into
the following groups: no anxiety or depression, anxiety,
depression and both anxiety and depression. Eighty-two
percent of the subjects reported no anxiety or depression
whatsoever, 11% reported anxiety, 2.5% depression, and 4%
both anxiety and depression.
All respiratory symptoms were more common in the
group with anxiety and depression symptoms than in the
group without anxiety and depression (Table 1). No asso-
ciation was found between psychological status andTable 1 Characteristics of the study sample (n Z 2270), % and
All No anxiety
depression
n Z 1870
Women 52% 50.7%
Age 42.7 (7) 43 (7)
Smoking habits
Never-smokers 24% 22.4%
Ex-smokers 13% 12.5%
Quitted smoking 20% 19.9%
Current smokers 43% 45.2%
Atopy 28% 28.2%
BMI (kg/m2) 25.7 (4.2) 25.7 (4.3
FEV1 (percent predicted) 103 (14) 103 (14)
Bronchial responsiveness 7.92 (2.1) 7.49 (1.8
Doctor-diagnosed asthma 19.9% 18.9%
Wheeze 29% 26.8%
Nocturnal chest tightness 16% 13.2%
Attack of breathlessn. after activity 16% 13.7%
Attack of breathlessn. when at rest 7% 4.9%
Breathlessness when wheezing 18% 16.0%
Wheeze when not having a cold 19% 16.6%
Nocturnal dyspnea 7% 5.4%smoking, atopy, lung function or bronchial responsiveness.
Anxiety was more common in women than men.
There was a significant association between psycholog-
ical status and all respiratory symptoms studied, after
adjusting for age, sex, smoking habits, atopy, BMI, bron-
chial responsiveness and FEV1 (Table 2). Participants with
higher bronchial responsiveness were more likely to report
respiratory symptoms. Also, atopy and BMI were signifi-
cantly associated with all respiratory symptoms except for
breathlessness at rest. Smoking was associated with prev-
alent wheeze. FEV1 was significantly lower in subjects with
respiratory symptoms except in the group that experienced
nocturnal chest tightness. In analyses of interactions be-
tween men and women, HADS score and respiratory symp-
toms showed no effect modifications (p-
values Z 0.37e0.76).
An analysis of the importance of the different de-
terminants in predicting respiratory symptoms showed that
the HADS score was the most important determinant for
nightly symptoms (nocturnal chest tightness or breathless-
ness) and the prevalence of attacks of breathlessness at
rest (Fig. 2). Bronchial responsiveness was the most
important determinant for wheezing and breathlessness
when wheezing. FEV1 was the most important determinant
for attacks of breathlessness after activity, but the HADS
score and bronchial responsiveness also had a strong asso-
ciation to this symptom.Discussion
The main finding was a strong association between experi-
encing respiratory symptoms and psychological status, but
this relationship varied depending on symptom.Mean (SD).
or Anxiety
n Z 250
Depression
n Z 56
Anxiety and
depression
n Z 94
p-Value
64.8% 47.1% 63.2% <0.001
42 (7) 44 (7) 42 (7) 0.052
26.9% 26.1% 31.1% 0.097
15.6% 11.6% 15.9%
19.1% 20.3% 15.2%
38.4% 42.0% 37.9%
25.1% 28.1% 25.7% 0.747
) 25.7 (4.3) 26.7 (6.0) 26.4 (5.1) 0.021
103 (15) 106 (13) 103 (16) 0.291
) 7.76 (1.8) 7.8 (1.8) 7.23 (2.2) 0.232
22.4% 22.4% 30.5% <0.01
41.3% 35.7% 45.9% <0.001
25.5% 20.0% 34.6% <0.001
18.5% 20.0% 33.1% <0.001
11.0% 11.4% 18.9% <0.001
25.2% 24.3% 32.6% <0.001
25.8% 24.3% 35.1% <0.001
13.4% 10.3% 16.5% <0.001
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1598 M. Leander et al.The HADS score was the most important determinant for
nightly symptoms (nocturnal chest tightness or dyspnea)
but also had a strong association with attacks of breath-
lessness at rest. This is in line with a study showing that
symptoms related to anxiety and especially depression are
important determinants for the development of respiratory
symptoms as dyspnea [30]. The prevalence of physician-
diagnosed asthma was very high in subjects with both
anxiety and depression. Other studies have also shown that
diagnosed asthma and current wheezing were associated
with diagnosed depression and anxiety [31,32]. An
increased risk of incident asthma at follow-up was found in
adults who reported symptoms of anxiety or depression at
baseline in a large prospective study on the general popu-
lation of Norway [33].
Anxiety was more common in women than men in our
study, which agrees with the results of another Swedish
study [34]. However, an analysis of interaction between
men and women in our study showed no significant effect
modification. Current smokers had the highest prevalence
of depression and current smoking was associated with
wheezing and wheezing when not having a cold.
As expected, increased bronchial responsiveness was
associated with all respiratory symptoms. Bronchial
responsiveness was the most important determinant for
wheezing and breathlessness. A close association between
wheezing and bronchial responsiveness has been shown in
other studies [35]. In the present study, FEV1 was a sig-
nificant determinant for four out of seven respiratory
symptoms (wheezing, breathlessness, wheezing when not
having cold and attack of breathlessness after activity) and
atopy was associated with respiratory symptoms except for
breathlessness at rest.
A high BMI was associated with an increased prevalence
of most respiratory symptoms. In a large meta-analysis
obesity was found to be independently associated with an
increased risk of incidence asthma [36]. The association
between obesity and asthma may, however, not be
completely straightforward. An Australian study showed
that subjects with severe obesity reported more wheezing
and shortness of breath but obesity was not associated with
atopy or airway hyper-responsiveness [37]. In a cross-
sectional multicenter study from Spain obesity was not
associated with a confirmed asthma diagnosis in patients
with asthma symptoms and a positive methacholine test.
However, obesity was suspected to be a risk factor for
development of asthma among non-atopic subjects [38]. A
Korean study of patients with an asthma diagnosis
confirmed by asthma specialists and methacholine test
showed that obesity was positively related to the preva-
lence of wheezing but inversely related to bronchial
hyperresponsiveness [39]. There are relatively few inter-
ventional studies but Mansiscalclo et al. found that lapa-
roscopic adjustable gastric banding lead to an improvement
in asthma symptoms in severely obese asthmatics [40] and
an improvement in asthma control was found in recent
study of a weight loss program for asthmatics [41].
The present study indicates that improving psychological
status may be a way forward in reducing respiratory
symptoms. Beneficial short and long-term effects of a brief
cognitive behavioral therapy designed to reduce asthma-
specific fear has been shown [42]. Behavioral therapeutic
Figure 2 Variable importance for the different outcomes as judged by Wald c2-predictor degrees of freedom.
Impact of anxiety and depression 1599programs may therefore offer an opportunity to reduce
anxiety and to improve asthma self-management in some
patients. It is, however, also likely that higher levels of
respiratory symptoms may also increase psychological
distress. The present study is cross sectional. It is therefore
not possible to know whether the association between
psychological status and respiratory symptoms is an effect
of anxiety and depression causing respiratory symptoms or
whether the cause and effect relationship is the opposite.
In conclusion, there is a strong association between
respiratory symptoms and psychological status. There is
therefore a need for interventional studies designed to
improve depression and anxiety in patients with respiratory
symptoms.Acknowledgments
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